Pharmaceuticals, Biotechnology and Life Sciences
Allergan has expanded the label of Avycaz, as it got approval from the US FDA for its supplemental New Drug Application (sNDA), for treating young patients with complicated intra-abdominal infections.
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Allergan’s Avycaz (ceftazidime and avibactam) for priority review.
Allergan has ensured permit to update the label for its Avycaz with new data from two third phase clinical trials, about treatining patients with certain complicated urinary tract infections (UTI).
Allergan’s researchers have presented data at IDWeek from the International Network for Optimal Resistance Monitoring (INFORM) program that monitors the prevalence of resistant bacteria and changing trends of resistance, as well as the in vitro activity of antibiotics against these pathogens.
FDA is warning health care professionals about the risk for dosing errors with the intravenous antibacterial drug Avycaz (ceftazidime and…